The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Path: ILD with a granulomatous component (see also Im)
Publications
Adalimumab-induced pulmonary sarcoidosis not progressing upon treatment with etanercept.
Zeitschrift fur Rheumatologie 2017 May;76;372-374 — 2017 May — 372-374
Hemidiaphragm paresis and granulomatous pneumonitis associated with adalimumab: a case report.
Heart & lung : the journal of critical care 2014 Jan-Feb;43;84-6 — 2014 Jan-Feb — 84-6